Related Experiment Video
Updated: May 14, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Dual Targeting Strategy: Colchicine and Paclitaxel Combination Against Prostate Cancer Cells Colchicine-Paclitaxel
Ceren Sumer1, Ceren Sari1, Mertkaya Aras1
1Health Institutes of Türkiye, Türkiye Cancer Institute, Ankara, Türkiye.
Objective:
Prostate cancer is the leading male malignancy. Despite therapeutic advances, drug resistance remains a major obstacle, leading many patients to develop castration-resistant prostate cancer. This study investigates the combined effects of the microtubule-targeting agents colchicine and paclitaxel on DU145 prostate cancer cells.
Methods:
Cell viability was evaluated across a range of doses of colchicine and paclitaxel to determine the IC50, IC30, and IC10 values for each drug. IC10 and IC30 doses of the agents and their combinations were selected for subsequent experiments. The effects of the treatments were then analyzed using the MTT assay, the colony formation assay, the in vitro scratch assay, and acridine orange/ethidium bromide staining.
Results:
Monotherapy with colchicine and paclitaxel indicated dose- and time-dependent cytotoxicity in DU145 cells. Notably, IC10 monotherapies had minimal impact on viability, whereas the drug combination produced synergistic inhibition of viability (excess‑over‑Bliss score: 14.8%), along with marked suppression of colony formation and cell motility (p<0.0001). At IC30, the combined treatment nearly abolished colony formation and significantly increased apoptotic and necrotic morphology. These findings reveal that combining sub-therapeutic doses effectively inhibits cell viability, long-term proliferation, and cell motility, where monotherapies are insufficient.
Conclusions:
These preliminary findings demonstrate that the colchicine and paclitaxel combination exhibits potent synergistic effects, particularly at low doses (IC10), and effectively suppresses DU145 prostate cancer cell progression. This dual microtubule-targeting approach may overcome the limitations of monotherapy by significantly inhibiting cell motility and clonogenic survival, while enhancing apoptotic and necrotic cell morphology. Our results suggest that low-dose combination strategies may provide high therapeutic efficacy while minimizing systemic toxicity in the management of advanced prostate cancer.
Insights
Combining low-dose colchicine and paclitaxel shows synergistic effects against prostate cancer cells, significantly inhibiting viability, motility, and colony formation. This dual microtubule-targeting strategy offers potential for enhanced efficacy with reduced toxicity in advanced prostate cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Prostate cancer is a leading male malignancy with significant drug resistance issues, often progressing to castration-resistant prostate cancer.
- Current therapies face limitations due to drug resistance, necessitating novel treatment strategies for advanced disease.
Purpose of the Study:
- To investigate the synergistic effects of combining microtubule-targeting agents, colchicine and paclitaxel, on DU145 prostate cancer cells.
- To evaluate the efficacy of low-dose combination therapy in inhibiting prostate cancer cell viability, proliferation, and motility.
Main Methods:
- Determined IC50, IC30, and IC10 values for colchicine and paclitaxel monotherapies.
- Assessed treatment effects using MTT assays, colony formation assays, in vitro scratch assays, and acridine orange/ethidium bromide staining.
- Analyzed synergistic effects using the excess-over-Bliss score.
Main Results:
- Combined low-dose (IC10) colchicine and paclitaxel demonstrated synergistic inhibition of cell viability (excess-over-Bliss score: 14.8%) and marked suppression of colony formation and cell motility (p<0.0001).
- At IC30 doses, the combination treatment nearly abolished colony formation and significantly increased apoptotic and necrotic cell morphology.
- Monotherapy with either agent at IC10 had minimal impact on cell viability, highlighting the synergistic advantage of the combination.
Conclusions:
- The combination of colchicine and paclitaxel exhibits potent synergistic effects against prostate cancer cells, particularly at low doses.
- This dual microtubule-targeting approach effectively suppresses cell viability, motility, and clonogenic survival, potentially overcoming monotherapy limitations.
- Low-dose combination strategies may offer high therapeutic efficacy with minimized systemic toxicity for advanced prostate cancer management.
More Related Videos
08:03Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:15Drugs that Stabilize Microtubules
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:10Drugs that Destabilize Microtubules
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...